{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:16:57Z","timestamp":1764173817617,"version":"3.40.2"},"reference-count":23,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ejca.2012.03.002","type":"journal-article","created":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T00:03:38Z","timestamp":1332893018000},"page":"1932-1938","source":"Crossref","is-referenced-by-count":42,"title":["Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer"],"prefix":"10.1016","volume":"48","author":[{"given":"Rupert","family":"Bartsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Bago-Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina","family":"DeVries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Pluschnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dubsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaretha","family":"Rudas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rottenfusser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Fitzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph C.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenther G.","family":"Steger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.03.002_b0005","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced beast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.03.002_b0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cncr.10239","article-title":"A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma","volume":"94","author":"Bajetta","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.03.002_b0015","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","article-title":"Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer","volume":"14","author":"Paridaens","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.03.002_b0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0022-3565(24)38923-2","article-title":"Molecular mechanisms of selective estrogen receptor modulator (SERM) action","volume":"295","author":"Dutertre","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2012.03.002_b0025","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.03.002_b0030","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1073\/pnas.87.17.6883","article-title":"Inhibition of estrogen receptor-DNA binding by the \u201cpure\u201d anti-estrogen ICI 164,384 appears to be mediated by impaired receptor dimerization","volume":"87","author":"Fawell","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2012.03.002_b0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/erc.0.0070017","article-title":"Similarities and distinctions in the mode of action of different classes of antioestrogens","volume":"7","author":"Wakeling","year":"2000","journal-title":"Endocr Relat Cancer"},{"issue":"2 Pt. 2","key":"10.1016\/j.ejca.2012.03.002_b0040","doi-asserted-by":"crossref","first-page":"865S","DOI":"10.1158\/1078-0432.865s.11.2","article-title":"Crosstalk between estrogen receptor and growth factor receptor pathways is a cause for endocrine resistance in breast cancer","volume":"11","author":"Osborne","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.03.002_b0045","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1677\/erc.1.00857","article-title":"Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer","volume":"12","author":"Normanno","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejca.2012.03.002_b0050","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/annonc\/mdp447","article-title":"Activity of fulvestrant in HER2-overexpressing advanced breast cancer","volume":"21","author":"Robertson","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.03.002_b0055","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.03.002_b0060","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.03.002_b0065","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1998.16.3.994","article-title":"Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study","volume":"16","author":"Taylor","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.03.002_b0070","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","volume":"19","author":"Klijn","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.03.002_b0075","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.03.002_b0080","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.ejca.2010.08.005","article-title":"Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women","volume":"46","author":"Cheung","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.03.002_b0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2006.08.019","article-title":"Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer","volume":"43","author":"Robertson","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.03.002_b0090","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.bjc.6601557","article-title":"Clinical and endocrine data for goserelin plus anastrozol as second-line endocrine therapy for premenopausal advanced breast cancer","volume":"90","author":"Forward","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2012.03.002_b0095","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.03.002_b0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","article-title":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women \u2013 a prospective combined analysis of two multicenter trials","volume":"98","author":"Robertson","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.03.002_b0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10549-008-0132-0","article-title":"The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer","volume":"115","author":"Bartsch","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2012.03.002_b0110","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.03.002_b0115","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1200\/JCO.2008.21.1136","article-title":"Activity of fulvestrant 500mg versus anastrozole 1mg as first-line treatment for advanced breast cancer: results from the FIRST study","volume":"27","author":"Robertson","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T03:51:06Z","timestamp":1742788266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491200247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S095980491200247X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.03.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}